BioSpace News Archive

Applied UV, Inc. (NASDAQ: AUVI), a leader in global food security, air quality, and specialty building solutions today announced preliminary financial results for the third quarter and nine months ended September 30, 2023, and reiterated its previous guidance of approximately $45 million in revenue for 2023.

Theriva™ Biologics reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced financial results and business highlights for the quarter ended September 30, 2023.

RAPT Therapeutics, Inc. today reported financial results for the third quarter and the nine months ended September 30, 2023.

Aligos Therapeutics, Inc. today announced that clinical and nonclinical data for its thyroid hormone receptor-beta (THR-b) drug, ALG-055009, were presented Saturday, November 11th at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), being held in Boston, Massachusetts, November 10 – 14, 2023.

Cocrystal Pharma, Inc. reports financial results for the three and nine months ended September 30, 2023, and provides updates on its antiviral pipeline, upcoming milestones and business activities.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of uveal melanoma (UM) metastatic to the liver (mUM) ( NCT00986661 ).

Daxor Corporation announces the presentation of data from a Phase I National Institute of Health sponsored randomized control trial from two Veterans Affairs Medical Centers, validating treatment decisions guided by the Company’s BVA-100® diagnostic blood test benefitted patients with acute decompensated heart failure.

Artelo Biosciences, Inc. today reported financial and operating results for the three months ended September 30, 2023 and provided a business update.